The focus of the EU funded network NeurASYN is alpha-synuclein (ASYN), a protein believed to play a key role in the pathogenesis of Parkinson’s disease and Multiple System Atrophy, Diffuse LB Disease, LB Variant of Alzheimer's Disease as well as others, collectively termed synucleinopathies.
The aim of NeurASYN is to create a network of European partners who will examine ASYN conformations, regulation, and mechanisms of toxicity, using state of the art in vitro assays, diverse cellular and animal models as well as structural biology, also including novel cellular and in vivo imaging modalities. Through this work, biomarkers and experimental therapeutics targeting ASYN will be tested.
This network will create the opportunity for training of a number of early stage researchers in the diverse fields of protein chemistry, biochemistry, cell biology, neurobiology, and animal modelling of nervous system diseases, within an interdisciplinary setting, while exposing them to both Academic and Industrial environments.
PhD: 3 years, Postdoc: 2 years
European academic und industry top labs
Dr H Graessner, Research Manager
University of Tübingen
Riess lab (Medical Genetics)